MacroGenics (MGNX) to Release Earnings on Monday

MacroGenics (NASDAQ:MGNX) will be issuing its quarterly earnings data after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of $2.62 per share for the quarter.

MacroGenics (NASDAQ MGNX) opened at $23.30 on Monday. MacroGenics has a 1-year low of $14.36 and a 1-year high of $24.26. The company has a market cap of $857.97, a price-to-earnings ratio of -5.19 and a beta of 2.79.

In other news, SVP Jon Marc Wigginton sold 5,000 shares of the company’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Eric Blasius Risser sold 3,000 shares of the company’s stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $22.50, for a total transaction of $67,500.00. Following the completion of the sale, the senior vice president now directly owns 12,100 shares in the company, valued at $272,250. The disclosure for this sale can be found here. Insiders sold a total of 13,000 shares of company stock worth $267,500 over the last ninety days. Insiders own 8.30% of the company’s stock.

MGNX has been the subject of several research reports. Cowen restated a “buy” rating on shares of MacroGenics in a report on Wednesday, October 25th. ValuEngine lowered shares of MacroGenics from a “sell” rating to a “strong sell” rating in a report on Tuesday, November 14th. BidaskClub raised shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. Citigroup upped their target price on shares of MacroGenics from $18.00 to $22.00 and gave the stock a “neutral” rating in a research report on Friday, November 10th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of MacroGenics in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the stock. MacroGenics has an average rating of “Buy” and an average price target of $30.60.

COPYRIGHT VIOLATION WARNING: “MacroGenics (MGNX) to Release Earnings on Monday” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://stocknewstimes.com/2018/02/19/macrogenics-mgnx-to-release-earnings-on-monday.html.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Earnings History for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply